Bausch + Lomb reports second-quarter results today with a fresh analyst endorsement landing just hours before the open — and options traders responding to the earnings date with the most defensive positioning seen in months.
The standout heading into this print is UBS initiating coverage with a Buy rating and a $21 target, issued on the same morning as the report. That target sits 26% above the current price of $16.61, making it the most bullish published view on the stock. It arrives alongside a consensus that is technically "buy" but thin — just four buy-rated analysts, with Evercore ISI sitting at In-Line and a mean target of $18.38. The gap between the UBS view and the Evercore caution captures the debate neatly: is this a leverage-burdened spinoff still finding its footing, or an ophthalmology franchise with underappreciated momentum?
That bull-bear tension has a clear shape. Bulls point to broad-based revenue growth across Vision Care, Surgical, and Pharmaceuticals in the most recent quarter, with MIEBO prescriptions up 110% year-over-year and premium IOL platforms recovering. Bears focus on the structural overhang: high leverage inherited from the Bausch Health relationship, a limited pipeline relative to Alcon and other pure-play peers, and macro sensitivity in elective procedures. The stock is up only 2% on the month despite the UBS catalyst, suggesting the market is waiting for the numbers rather than rewarding the endorsement in advance.
Options positioning confirms that caution. The put/call ratio moved to 0.106 on the eve of the report — more than 2.4 standard deviations above its 20-day average of 0.074. That is the most elevated hedging demand seen in the options market for this name in months, even though the absolute ratio remains low by broader market standards. The borrow market, by contrast, tells a much calmer story. Short interest has declined roughly 13% over the past month to just over 1% of the free float, and availability has loosened sharply — now at 373%, compared to levels below 50% in late June. With short interest low and borrowing costs near 0.69%, there is no meaningful short-side pressure feeding into the print.
Prior earnings reactions for BLCO have been contained. The April print produced a 1-day move of just over 1%, settling to a 5-day gain of roughly 1.8%. The May event was essentially flat on day one, drifting slightly lower over five days. That pattern — modest moves in either direction — sets a low bar for surprises. Today's print will test whether the UBS thesis on MIEBO momentum and premium IOL recovery can be substantiated with second-quarter numbers that justify a target sitting well above where most of the Street currently sits.
See the live data behind this article on ORTEX.
Open BLCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
